758 related articles for article (PubMed ID: 27784340)
21. Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8
Chen D; Huang L; Zhou H; Zhang Y
Front Immunol; 2021; 12():615089. PubMed ID: 33717103
[TBL] [Abstract][Full Text] [Related]
22. Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer.
McGray AJR; Huang RY; Battaglia S; Eppolito C; Miliotto A; Stephenson KB; Lugade AA; Webster G; Lichty BD; Seshadri M; Kozbor D; Odunsi K
J Immunother Cancer; 2019 Jul; 7(1):189. PubMed ID: 31315674
[TBL] [Abstract][Full Text] [Related]
23. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
[TBL] [Abstract][Full Text] [Related]
25. Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.
Saha D; Martuza RL; Rabkin SD
Immunotherapy; 2018 Jul; 10(9):779-786. PubMed ID: 30008259
[TBL] [Abstract][Full Text] [Related]
26. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma.
Wong RJ; Patel SG; Kim S; DeMatteo RP; Malhotra S; Bennett JJ; St-Louis M; Shah JP; Johnson PA; Fong Y
Hum Gene Ther; 2001 Feb; 12(3):253-65. PubMed ID: 11177562
[TBL] [Abstract][Full Text] [Related]
27. Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma.
Zhang L; Wang W; Wang R; Zhang N; Shang H; Bi Y; Chen D; Zhang C; Li L; Yin J; Zhang H; Cao Y
Mol Ther; 2021 Feb; 29(2):744-761. PubMed ID: 33130310
[TBL] [Abstract][Full Text] [Related]
28. Advance in herpes simplex viruses for cancer therapy.
Liu S; Dai M; You L; Zhao Y
Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
[TBL] [Abstract][Full Text] [Related]
29. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
[No Abstract] [Full Text] [Related]
30. Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft.
Tan G; Kasuya H; Sahin TT; Yamamura K; Wu Z; Koide Y; Hotta Y; Shikano T; Yamada S; Kanzaki A; Fujii T; Sugimoto H; Nomoto S; Nishikawa Y; Tanaka M; Tsurumaru N; Kuwahara T; Fukuda S; Ichinose T; Kikumori T; Takeda S; Nakao A; Kodera Y
Int J Cancer; 2015 Apr; 136(7):1718-30. PubMed ID: 25156870
[TBL] [Abstract][Full Text] [Related]
31. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
Wang J; Hu P; Zeng M; Rabkin SD; Liu R
Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
[TBL] [Abstract][Full Text] [Related]
32. An oncolytic herpes simplex virus type 1 strain expressing a single-chain variable region antibody fragment against PD-1 and a PI3K inhibitor synergize to elicit antitumor immunity in ovarian cancer.
Huang S; Hu H; Tang G; Liu K; Luo Z; Zeng W
Arch Virol; 2023 Mar; 168(4):128. PubMed ID: 37002434
[TBL] [Abstract][Full Text] [Related]
33. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms.
Nakamori M; Fu X; Meng F; Jin A; Tao L; Bast RC; Zhang X
Clin Cancer Res; 2003 Jul; 9(7):2727-33. PubMed ID: 12855653
[TBL] [Abstract][Full Text] [Related]
34. Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer.
Matuszewska K; Santry LA; van Vloten JP; AuYeung AWK; Major PP; Lawler J; Wootton SK; Bridle BW; Petrik J
Clin Cancer Res; 2019 Mar; 25(5):1624-1638. PubMed ID: 30206160
[TBL] [Abstract][Full Text] [Related]
35. Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents.
González-Pastor R; Ashshi AM; El-Shemi AG; Dmitriev IP; Kashentseva EA; Lu ZH; Goedegebuure SP; Podhajcer OL; Curiel DT
J Ovarian Res; 2019 Feb; 12(1):18. PubMed ID: 30767772
[TBL] [Abstract][Full Text] [Related]
36. Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.
Yoo JY; Pradarelli J; Haseley A; Wojton J; Kaka A; Bratasz A; Alvarez-Breckenridge CA; Yu JG; Powell K; Mazar AP; Teknos TN; Chiocca EA; Glorioso JC; Old M; Kaur B
Clin Cancer Res; 2012 Sep; 18(18):4931-41. PubMed ID: 22753591
[TBL] [Abstract][Full Text] [Related]
37. Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.
Antoszczyk S; Spyra M; Mautner VF; Kurtz A; Stemmer-Rachamimov AO; Martuza RL; Rabkin SD
Neuro Oncol; 2014 Aug; 16(8):1057-66. PubMed ID: 24470552
[TBL] [Abstract][Full Text] [Related]
38. An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer.
Zeng WG; Li JJ; Hu P; Lei L; Wang JN; Liu RB
Oncol Rep; 2013 Jun; 29(6):2355-61. PubMed ID: 23525624
[TBL] [Abstract][Full Text] [Related]
39. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
40. Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.
Leoni V; Gatta V; Palladini A; Nicoletti G; Ranieri D; Dall'Ora M; Grosso V; Rossi M; Alviano F; Bonsi L; Nanni P; Lollini PL; Campadelli-Fiume G
Oncotarget; 2015 Oct; 6(33):34774-87. PubMed ID: 26430966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]